Table 1. Patient characteristics.
| Overall n = 27 | |
|---|---|
| Age, median (range), years | 51 (33–79) |
| Comorbidity | |
| Diabetes | 2 (7.4%) |
| CHD | 1 (3.7%) |
| COPD | 0 |
| Hypertension | 0 |
| Pathology | |
| Invasive ductal carcinoma | 26 (96.3%) |
| Invasive lobular carcinoma | 1 (3.7%) |
| WHO grade | |
| I | 1 (3.7%) |
| II | 19 (70.4%) |
| III | 7 (25.9%) |
| ER | |
| Positive | 14 (51.9%) |
| Negative | 12 (44.4%) |
| Unknown | 1 (3.7%) |
| PR | |
| Positive | 10 (37.0%) |
| Negative | 16 (59.3%) |
| Unknown | 1 (3.7%) |
| HER2 | |
| Positive | 16 (59.3%) |
| Negative | 10 (37.0%) |
| Unknown | 1 (3.7%) |
| TNBC | |
| Yes | 4 (14.8%) |
| No | 22 (81.5%) |
| Unknown | 1 (3.7%) |
| Ki-67, median (range), % | 35 (5–80) |
| Number of brain metastasis, median (range) | 3 (1–9) |
| Extracranial metastasis | |
| Bone metastasis | 12 (44.4%) |
| Lung metastasis | 15 (55.6%) |
| Liver metastasis | 7 (25.9%) |
| Other metastasis | 10 (37.0%) |
Note:
CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor; TNBC, triple-negative breast cancer.